Metagenomi, Inc. (NASDAQ: MGX) had its price target lowered by analysts at HC Wainwright from $14.00 to $7.00. They now have a "buy" rating on the stock.
Metagenomi, Inc. (NASDAQ: MGX) had its price target lowered by analysts at Wells Fargo & Company from $25.00 to $20.00. They now have an "overweight" rating on the stock.
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference